AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00211653
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01211249
Drug: GLPG0259 (Part B)
RxNorm normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, dosage to be established based on results of Part A
Trial: NCT01497587
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose, 0.5 U/kg, administered s.c. (under the skin)
Trial: NCT02597660
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active drug
Trial: NCT03612960
Drug: Very low nicotine content cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Very low nicotine content cigarettes
Trial: NCT03612960
Drug: Normal nicotine content cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal nicotine content cigarettes
Trial: NCT01294670
Drug: Vorinostat and Etoposide
RxNorm normalized name: Vorinostat
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
Trial: NCT01405261
Drug: oral NNC 0113-0987
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
Trial: NCT01317589
Drug: methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%
Trial: NCT01142635
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
Trial: NCT01142635
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
Trial: NCT02378935
Drug: VOX
RxNorm normalized name: Luvox
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablet(s) administered orally once daily with food
Trial: NCT02378935
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT04435197
Drug: Pembrolizumab Injection
RxNorm normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-operative Pembrolizumab+chemoradiotherapy
Trial: NCT00958451
Drug: Paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.
Trial: NCT00958451
Drug: Ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.
Trial: NCT00096447
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01375920
Drug: Metyrapone
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 milligrams to be taken twice a day orally
Trial: NCT00477945
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort N Clofarabine (mg/m2/day)~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70
Trial: NCT02277847
Drug: Idarubicin(8mg/m2) and cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
Trial: NCT02277847
Drug: Idarubicin(10mg/m2), cytosine arabinoside
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
Trial: NCT00517595
Drug: Pemetrexed and Gemcitabine plus Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m\^2 and gemcitabine 1500 mg/m\^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
Trial: NCT03596294
Drug: Clazosentan
RxNorm normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
Trial: NCT03596294
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single i.v. dose of 600 mg rifampicin for 30 min
Trial: NCT01957930
Drug: Intensified insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
Trial: NCT04507659
Drug: Jaktinib Hydrochloride Tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.
Trial: NCT04507659
Drug: Jaktinib Hydrochloride Tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.
Trial: NCT00661531
Drug: Estrace
RxNorm normalized name: Estrace
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrace 10 mg three times daily will be administered for 3 months.
Trial: NCT00032396
Drug: Retisert Implant
RxNorm normalized name: fluocinolone Drug Implant [Retisert]
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02603003
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to the individual patient's condition
Trial: NCT02603003
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: According to the individual patient's condition
Trial: NCT00661531
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
Trial: NCT02920385
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration once daily alone or together with levothyroxine or Placebo
Trial: NCT00320034
Drug: R-albuterol, S-albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04244097
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
Trial: NCT04244097
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
Trial: NCT04158245
Drug: 18F-fluciclovine PET Scan
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
Trial: NCT00755313
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00755313
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02300103
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT00088192
Drug: pegaptanib sodium
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01477983
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
Trial: NCT01796171
Drug: 40 mg lilotomab
RxNorm normalized name: Lilotomab
DrugBank: Lilotomab (DB19076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796171
Drug: 100 mg/m2 lilotomab
DrugBank: Lilotomab (DB19076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796171
Drug: 60 mg/m2 lilotomab
DrugBank: Lilotomab (DB19076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796171
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00060346
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
Trial: NCT00060346
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions.
Trial: NCT00245063
Drug: cediranib maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00272909
Drug: piclozotan low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Piclozotan (DB12361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion over a period of up to 72 hours of piclozotan
Trial: NCT00272909
Drug: piclozotan high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Piclozotan (DB12361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion over a period of up to 72 hours of piclozotan
Trial: NCT00071071
Drug: HuMax-CD4
RxNorm normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
Trial: NCT02955641
Drug: Dexamethasone Disodium Phosphate 0.1%
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: four drops a day for four days after LPI treatment
Trial: NCT00071071
Drug: HuMax-CD4
RxNorm normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
Trial: NCT01379274
Drug: Lenalidomide and azacitidine combination
RxNorm normalized name: Azacitidine
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy.
Trial: NCT01309659
Drug: iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
Trial: NCT01309659
Drug: iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
Trial: NCT03443674
Drug: SCB-313
RxNorm normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized powder in a single-use vial
Trial: NCT01605162
Drug: TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
Trial: NCT02820311
Drug: TD-4208 175 mcg
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: via nebulizer
Trial: NCT02820311
Drug: TD-4208 700 mcg
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: via nebulizer
Trial: NCT02820311
Drug: Moxifloxacin 400 mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04621370
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
Trial: NCT01709149
Drug: CK-2017357
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CK-2017357 125 mg tablets twice daily
Trial: NCT02471820
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
Trial: NCT01709149
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02471820
Drug: Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
Trial: NCT02471820
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
Trial: NCT03382795
Drug: EGFR
RxNorm normalized name: VEGFR2-169
DrugBank: VEGFR2-169 (DB16152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
Trial: NCT04527107
Drug: THR-149 dose level 1
RxNorm normalized name: Thr
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 intravitreal injections of THR-149 dose level 1, 1 month apart
Trial: NCT04527107
Drug: THR-149 dose level 2
RxNorm normalized name: Thr
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 intravitreal injections of THR-149 dose level 2, 1 month apart
Trial: NCT04527107
Drug: THR-149 dose level 3
RxNorm normalized name: Thr
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 intravitreal injections of THR-149 dose level 3, 1 month apart
Trial: NCT04527107
Drug: THR-149 0.13mg + aflibercept 2mg
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
Trial: NCT04527107
Drug: aflibercept 2mg + THR-149 0.13mg
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
Trial: NCT04527107
Drug: Aflibercept 2mg
RxNorm normalized name: AFLIBERCEPT 2MG/0.05ML INJ,OPH
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
Trial: NCT05198947
Drug: Permethrin Lotion 5%
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
Trial: NCT05198947
Drug: Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
Trial: NCT00811135
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
Trial: NCT00811135
Drug: trastuzumab [Herceptin]
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
Trial: NCT00395694
Drug: lamictal
RxNorm normalized name: Lamictal
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti-epileptic drug
Trial: NCT00651131
Drug: daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daptomycin i.v. 4 mg/kg q24h for 7-14 days